Nanobiotix S.A. American Depositary Shares NBTX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T09:04:34.973Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.443324905Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T09:04:34.425476+00:00
Nanobiotix S.A. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 29.74 | 130.1% | 13.4% | |||
| 55Δ | 28.83 | 126.1% | 11.6% | |||
| 60Δ | 27.91 | 122.1% | 9.7% | 30.83 | 93.4% | 4.9% |
| 65Δ | 27.00 | 118.1% | 7.9% | 31.88 | 95.5% | 4.1% |
| 70Δ | 26.08 | 114.1% | 6.0% | 32.92 | 97.6% | 3.4% |
| 75Δ | 25.16 | 110.1% | 4.2% | 33.97 | 99.8% | 2.7% |
| 80Δ | 23.55 | 128.9% | 3.5% | 35.04 | 102.0% | 2.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 29.74
- IV
- 130.1%
- B/E move
- 13.4%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 28.83
- IV
- 126.1%
- B/E move
- 11.6%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 27.91
- IV
- 122.1%
- B/E move
- 9.7%
- Pseudo strike
- 30.83
- IV
- 93.4%
- B/E move
- 4.9%
65Δ
- Pseudo strike
- 27.00
- IV
- 118.1%
- B/E move
- 7.9%
- Pseudo strike
- 31.88
- IV
- 95.5%
- B/E move
- 4.1%
70Δ
- Pseudo strike
- 26.08
- IV
- 114.1%
- B/E move
- 6.0%
- Pseudo strike
- 32.92
- IV
- 97.6%
- B/E move
- 3.4%
75Δ
- Pseudo strike
- 25.16
- IV
- 110.1%
- B/E move
- 4.2%
- Pseudo strike
- 33.97
- IV
- 99.8%
- B/E move
- 2.7%
80Δ
- Pseudo strike
- 23.55
- IV
- 128.9%
- B/E move
- 3.5%
- Pseudo strike
- 35.04
- IV
- 102.0%
- B/E move
- 2.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 82.45% | |
| 74.01% | |
| 83.99% | |
| 84.40% | |
| 86.00% |
Biotechnology
NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and…
More →NRXP
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders…
More →